IP Library Granted Patent US 9,920,041
Granted Patent B2
US 9,920,041 · App. 15/439,705 · Granted Mar 20, 2018

Compositions and methods for inhibition of the JAK pathway

Inventors: Hui Li (Santa Clara, CA); Thilo J. Heckrodt (San Francisco, CA); Yan Chen (Foster City, CA); Darren John McMurtrie (Daly City, CA); Vanessa Taylor (San Francisco, CA); Rajinder Singh (Belmont, CA); Pingyu Ding (Foster City, CA); Rose Yen (San Francisco, CA)
Assignee: Rigel Pharmaceuticals, Inc.
C07D413/12C07B59/002C07F9/65583C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,920,041
App. No.
15/439,705
Granted
Mar 20, 2018
Kind
B2
Abstract

Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.

Claims (29)

1. A compound of formula IA:

or salt thereof, wherein:

R 1 is H, optionally substituted C 1-6 alkyl, C(O)—C 1-6 alkyl, CO 2 —C 1-6 alkyl or R 50 ;

each R 50 is —C(R 9 ) 2 -A-R 10 , where A is O or S; each R 9 is independently for each occurrence H, optionally substituted C 1-6 alkyl, optionally substituted C 6-10 aryl or optionally substituted C 7-16 arylalkyl; or alternatively, two R 9 , together with the carbon to which they are attached, form an optionally substituted C 3-8 cycloalkyl group or an optionally substituted 3-8 membered heteroalicyclyl; R 10 is R a , —P(O)(OR 11 ) 2 , —P(O)(OR 11 )N(R 12 ) 2 or —P(O)(N(R 12 ) 2 ) 2 ; each R 11 is independently for each occurrence R a or a monovalent cationic group; or two R 11 , together with the atoms to which they are attached, form a 4-8 membered cyclic phosphate group; each R 12 is independently for each occurrence R c or —C 1-3 alkyl-N(R c ) 2 ; or two R 12 , each on separate nitrogens of —P(O)(N(R 12 ) 2 ) 2 , together with the atoms to which they are attached, form a 4-8 membered cyclic phosphonic acid bisamide group; or one R 12 along with R 11 , of the group —P(O)(OR 11 )N(R 12 ) 2 , together with the atoms to which they are attached, form a 4-8 membered cyclic phosphonamidate group;

each of R 2a-2c is independently for each occurrence H, R e , R b , R e substituted with one or more of the same or different R a and/or R b , —OR e substituted with one or more of the same or different R a and/or R b , —SR e substituted with one or more of the same or different R a and/or R b , —C(O)R e substituted with one or more of the same or different R a and/or R b , —N(R a )R e where R e is substituted with one or more of the same or different R a and/or R b , —S(O) 2 R e substituted with one or more of the same or different R a and/or R b , —N(R a )—S(O) 2 R e where R e is substituted with one or more of the same or different R a and/or R b , —B(OR a ) 2 , —B(N(R c ) 2 ) 2 , —(C(R a ) 2 ) m —R b , —O—(C(R a ) 2 ) m —R b , —S—(C(R a ) 2 ) m —R b , —O—(C(R b ) 2 ) m —R a , —N(R a )—(C(R a ) 2 ) m —R b , —O—(CH 2 ) m —CH((CH 2 ) m R b )R b , —C(O)N(R a )—(C(R a ) 2 ) m —R b , —O—(C(R a ) 2 ) m —C(O)N(R a )—(C(R a ) 2 ) m —R b , —N((C(R a ) 2 ) m R b ) 2 , —S—(C(R a ) 2 ) m —C(O)N(R a )—(C(R a ) 2 ) m —R b , —N(R a )—C(O)—N(R a )—(C(R a ) 2 ) m —R b , —N(R a )—C(O)—(C(R a ) 2 ) m —C(R a )(R b ) 2 or —N(R a )—(C(R a ) 2 ) m —C(O)—N(R a )—(C(R a ) 2 ) m —R b ;

R 2d is F;

R 2e is halo or optionally substituted C 1-6 alkyl;

each R a is independently for each occurrence H, deuterium, C 1-6 alkyl, C 3-8 cycloalkyl, C 4-11 cycloalkylalkyl, C 6-10 aryl, C 7-16 arylalkyl, 2-6 membered heteroalkyl, 3-10 membered heteroalicyclyl, 4-11 membered heteroalicyclylalkyl, 5-15 membered heteroaryl or 6-16 membered heteroarylalkyl;

each R b is independently for each occurrence ═O, —OR a , —O—(C(R a ) 2 ) m —OR a , haloC 1-3 alkyloxy, ═S, —SR a , ═NR a , ═NOR a , —N(R c ) 2 , halo, —CF 3 , —CN, —NC, —OCN, —SCN, —NO, —NO 2 , ═N 2 , —N 3 , —S(O)R a , —S(O) 2 R a , —SO 3 R a , —S(O)N(R c ) 2 , —S(O) 2 N(R c ) 2 , —OS(O)R a , —OS(O) 2 R a , —OSO 3 R a , —OS(O) 2 N(R c ) 2 , —C(O)R a , —CO 2 R a , —C(O)N(R c ) 2 , —C(NR a )—N(R c ) 2 , —C(NOH)—R a , —C(NOH)—N(R c ) 2 , —OC(O)R a , —OC(O)OR a , —OC(O)N(R c ) 2 , —OC(NH)—N(R c ) 2 , —OC(NR a )—N(R c ) 2 , —N(R a )—S(O) 2 H, —[N(R a )C(O)] n R a , —[N(R a )C(O)] n OR a , —[N(R a )C(O)] n N(R c ) 2 or —[N(R a )C(NR a )] n —N(R c ) 2 ;

each R c is independently for each occurrence R a , or, alternatively, two R c are taken together with the nitrogen atom to which they are bonded to form a 3 to 10-membered heteroalicyclyl or a 5-10 membered heteroaryl optionally comprising one or more of the same or different additional heteroatoms and which is optionally substituted with one or more of the same or different R a and/or R d groups;

each R d is ═O, —OR a , haloC 1-3 alkyloxy, C 1-6 alkyl, ═S, —SR a , ═NR a , ═NOR a , —N(R a ) 2 , halo, —CF 3 , —CN, —NC, —OCN, —SCN, —NO, —NO 2 , ═N 2 , —N 3 , —S(O)R a , —S(O 2 )R a , —SO 3 R a , —S(O)N(R a ) 2 , —S(O) 2 N(R a ) 2 , —OS(O)R a , —OS(O) 2 R a , —OSO 3 R a , —OS(O) 2 N(R a ) 2 , —C(O)R a , —CO 2 R a , —C(O)N(R a ) 2 , —C(NR a )N(R a ) 2 , —C(NOH)R a , —C(NOH)N(R a ) 2 , —OCO 2 R a , —OC(O)N(R a ) 2 , —OC(NR a )N(R a ) 2 , —[N(R a )C(O)] n R a , —(C(R a ) 2 ) n —OR a , —N(R a )—S(O) 2 R a , —C(O)—C 1-6 haloalkyl, —S(O) 2 C 1-6 haloalkyl, —OC(O)R a , —O(C(R a ) 2 ) m —OR a , —S(C(R a ) 2 ) m —OR a , —N(R a )C 1-6 haloalkyl, —P(O)(OR a ) 2 , —N(R a )—(C(R a ) 2 ) m —OR a , —[N(R a )C(O)] n OR a , —[N(R a )C(O)] n N(R a ) 2 , —[N(R a )C(NR a )] n N(R a ) 2 or —N(R a )C(O)C 1-6 haloalkyl;

two R d , taken together with the atom or atoms to which they are attached, combine to form a 3-10 membered partially or fully saturated mono or bicyclic ring, optionally containing one or more heteroatoms and optionally substituted with one or more R a ;

each R e is independently for each occurrence C 1-6 alkyl, C 3-8 cycloalkyl, C 4-11 cycloalkylalkyl, C 6-10 aryl, C 7-16 arylalkyl, 2-6 membered heteroalkyl, 3-10 membered heteroalicyclyl, 4-11 membered heteroalicyclylalkyl, 5-15 membered heteroaryl or 6-16 membered heteroarylalkyl;

each m is 1, 2 or 3;

each n is 0, 1, 2 or 3;

two of R 2a-2c groups, taken together with the atom or atoms to which they are attached, combine to form a 4-10 membered partially or fully saturated mono or bicyclic ring, optionally containing one or more heteroatoms and optionally substituted with one or more R a and/or R b ;

R 4 is H or optionally substituted C 1-6 alkyl; and

R 5 is H, halo, —CN, optionally substituted C 1-6 alkyl, nitro, —N(R a ) 2 , —C(O)N(R a ) 2 , —CO 2 R a or —C(O)R a .

2. The compound of claim 1 , wherein R 2a is H; R 2b is C 1-3 alkyl; and R 2c is —OC 1-3 alkyl.

3. The compound of claim 2 , wherein R 2a is H; R 2b is CH 3 ; and R 2c is —OCH 3 .

4. The compound of claim 1 , wherein R 2a is H; R 2b is —OC 1-3 alkyl; and R 2c is —OC 1-3 alkyl.

5. The compound of claim 4 , wherein R 2a is H; R 2b is —OC 1-3 alkyl; and R 2c is —OC 1-3 alkyl.

6. The compound of claim 5 , wherein R 2a is H; R 2b is —OCH 3 ; and R 2c is —OCH 3 .

7. The compound of claim 1 , wherein R 2a , R 2b and R 2c are each independently CH 3 , —OCH 3 , or F.

8. The compound of claim 7 , wherein two of R 2a , R 2b and R 2c are CH 3 ; and the other of R 2a , R 2b and R 2c is F.

9. The compound of claim 7 , wherein two of R 2a , R 2b and R 2c are CH 3 ; and the other of R 2a , R 2b and R 2c is —OCH 3 .

10. The compound of claim 7 , wherein two of R 2a , R 2b and R 2c are —OCH 3 ; and the other of R 2a , R 2b and R 2c is F.

11. The compound of claim 7 , wherein two of R 2a , R 2b and R 2c are —OCH 3 ; and the other of R 2a , R 2b and R 2c is CH 3 .

12. The compound of claim 7 , wherein one of R 2a , R 2b and R 2c is CH 3 ; one of R 2a , R 2b and R 2c is —OCH 3 ; and one of R 2a , R 2b and R 2c is F.

Assignments (2)
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2017
From: LI, HUI; HECKRODT, THILO J.; CHEN, YAN; MCMURTRIE, DARREN JOHN; TAYLOR, VANESSA; SINGH, RAJINDER; DING, PINGYU; YEN, ROSE
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 042046/0577 →
Continuity (5)
Continuation 14725932 · May 29, 2015
Continuation 13685433 · Nov 26, 2012
Continuation 13192344 · Jul 27, 2011
Provisional Application 61368570 · Jul 28, 2010
Related Publication 20170158683A1 · Jun 8, 2017